OncoCyte Corporation

NasdaqCM:OCX Stock Report

Market Cap: US$33.3m

OncoCyte Valuation

Is OCX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of OCX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate OCX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate OCX's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for OCX?

Other financial metrics that can be useful for relative valuation.

OCX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue21.2x
Enterprise Value/EBITDA-1.5x
PEG Ration/a

Price to Sales Ratio vs Peers

How does OCX's PS Ratio compare to its peers?

The above table shows the PS ratio for OCX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average24.3x
ONCT Oncternal Therapeutics
31.1x0.8%US$24.6m
APLM Apollomics
45.7x56.4%US$38.1m
TTOO T2 Biosystems
3.7x36.3%US$29.5m
SABS SAB Biotherapeutics
16.9x-100.0%US$39.6m
OCX OncoCyte
22.7x54.2%US$33.3m

Price-To-Sales vs Peers: OCX is good value based on its Price-To-Sales Ratio (22.7x) compared to the peer average (24.3x).


Price to Earnings Ratio vs Industry

How does OCX's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a23.2%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a23.2%
n/an/an/a
No more companies

Price-To-Sales vs Industry: OCX is expensive based on its Price-To-Sales Ratio (22.7x) compared to the US Biotechs industry average (13.5x).


Price to Sales Ratio vs Fair Ratio

What is OCX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

OCX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio22.7x
Fair PS Ratio6.4x

Price-To-Sales vs Fair Ratio: OCX is expensive based on its Price-To-Sales Ratio (22.7x) compared to the estimated Fair Price-To-Sales Ratio (6.4x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst OCX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$2.55
US$4.06
+59.3%
17.6%US$5.00US$3.00n/a4
Apr ’25US$2.98
US$3.53
+18.6%
11.6%US$4.00US$3.00n/a3
Mar ’25US$3.00
US$3.53
+17.8%
11.6%US$4.00US$3.00n/a3
Feb ’25US$2.93
US$3.90
+33.1%
18.7%US$5.00US$3.00n/a4
Jan ’25US$2.50
US$3.90
+56.0%
18.7%US$5.00US$3.00n/a4
Dec ’24US$3.88
US$3.90
+0.5%
18.7%US$5.00US$3.00n/a4
Nov ’24US$2.30
US$4.19
+82.1%
12.9%US$5.00US$3.50n/a4
Oct ’24US$3.12
US$4.19
+34.2%
12.9%US$5.00US$3.50n/a4
Sep ’24US$3.47
US$4.19
+20.7%
12.9%US$5.00US$3.50n/a4
Aug ’24US$4.13
US$7.00
+69.5%
30.3%US$9.00US$4.00n/a4
Jul ’24US$4.60
US$7.00
+52.2%
30.3%US$9.00US$4.00n/a4
Jun ’24US$4.55
US$7.00
+53.7%
30.3%US$9.00US$4.00n/a4
May ’24US$5.50
US$9.00
+63.7%
7.9%US$10.00US$8.00US$2.554
Apr ’24US$7.09
US$16.50
+132.8%
48.8%US$28.00US$8.00US$2.984
Mar ’24US$6.96
US$16.50
+137.1%
48.8%US$28.00US$8.00US$3.004
Feb ’24US$7.80
US$16.50
+111.5%
48.8%US$28.00US$8.00US$2.934
Jan ’24US$6.42
US$19.00
+196.0%
33.7%US$28.00US$10.00US$2.504
Dec ’23US$9.50
US$25.20
+165.2%
73.9%US$60.00US$10.00US$3.885
Nov ’23US$14.14
US$46.67
+230.0%
43.0%US$80.00US$18.00US$2.306
Oct ’23US$14.60
US$47.50
+225.3%
39.9%US$80.00US$23.00US$3.126
Sep ’23US$15.77
US$47.50
+201.2%
39.9%US$80.00US$23.00US$3.476
Aug ’23US$16.50
US$63.00
+281.8%
53.5%US$120.00US$25.00US$4.136
Jul ’23US$17.04
US$63.00
+269.7%
53.5%US$120.00US$25.00US$4.606
Jun ’23US$19.81
US$63.00
+218.0%
53.5%US$120.00US$25.00US$4.556
May ’23US$23.20
US$100.33
+332.5%
58.5%US$220.00US$40.00US$5.506

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.